摘要
利妥昔单抗(Rituximab,RTX)是一种人鼠嵌合型单克隆抗体,特发性膜性肾病(idiopathic membranous nephropathy,IMN)是由针对肾小球足细胞分子的自身抗体所致。文章综述RTX在IMN中应用的研究进展,从而为IMN的临床治疗提供重要的理论依据和新思路。
Rituximab(RTX)is a human-mouse chimeric monoclonal antibody.Idiopathic membranous nephropathy(IMN)is caused by auto-antibodies against glomerular podocyte molecules.This paper reviews the application of RTX in IMN to provide important theoretical basis and new ideas for clinical treatment of IMN.
作者
卢婉君
龚书豪
李娟
王缨
LU Wan-jun;GONG Shu-hao;LI Juan;WANG Ying(Department of Medicine,the First Affiliated Hospital,Nanchang University,Nanchang 330006,China;Department of Nephrology,the First Affiliated Hospital,Nanchang University,Nanchang 330006,China)
出处
《实用临床医学（江西）》
CAS
2020年第1期99-102,107,共5页
Practical Clinical Medicine
